Board of Directors
Geoffery M. Glass, Chairman
Mr. Geoffrey M. Glass was elected to the board of directors in July of 2018. He is also a member of the board of Sancilio Pharmaceuticals, a specialty pharma company where he was also previously the CEO. Prior to Sancilio, Mr. Glass was President of Clear Sciences, LLC, a management consulting company focused on life sciences industries. From 2009 – 2015, Mr. Glass served as an executive committee member at Patheon and held a number of senior leadership roles including President of Banner Life Sciences, a business unit of Patheon Pharmaceuticals, Executive Vice President of Sales and Marketing for Patheon Pharmaceuticals, and as Senior Vice President, Strategy, Corporate Development and Integration. Before Patheon, Mr. Glass worked in various executive positions at Valeant Pharmaceuticals, including Senior Vice President, Asia Region, Senior Vice President, Chief Information Officer and as member of the executive committee. Mr. Glass began his career as a consultant in the Life Sciences practice for Capgemini Consulting (formerly EY Consulting). He received degrees in Economics and Political Science from the University of Arizona.
The Honorable Craig Stapleton
The Honorable Craig Stapleton has been a member of the Board of Directors since June 2011, becoming Chairman in July 2014.
He is a member of Avadel’s Compensation, Audit, and Nominating & Corporate Governance Committees. Since January 2009, Mr. Stapleton has served as Senior Advisor to Stone Point Capital, a private equity firm. He was President of Marsh and McLennan Real Estate Advisors of New York from 1982 until 2001. From 1989 to 1998 Stapleton co-owned the Texas Rangers baseball team with George W. Bush. He has served on the Board of Directors for companies including Allegheny Properties, IDS Realty Inc., Investors Savings and Loan, Metro PCS, TB Woods, Abercrombie and Fitch, and Carlile Bank. In July 2009, he became a co-owner of the St. Louis Cardinals. Mr. Stapleton currently serves as a Director of Vivino and Tenax Aerospace.
Stapleton served on the Board of the Peace Corps. He was Ambassador to the Czech Republic from 2001 to 2003 and received the Jan Masaryk Medal from the Czech Republic. In June 2005, he was appointed Ambassador to France, serving until January 2009. He was awarded the French Legion of Honor as a Commander.
He is the Chairman of the Vaclav Havel Foundation and Chairman of the American Friends of Compiegne. He is a Trustee of the George W. Bush Library Foundation and the American University in Paris. He is a member of the Board of Directors of the 9/11 Memorial & Museum.
With his experience as Ambassador, and the Chairman and Director of several public and private companies, Mr. Stapleton brings to Avadel over 40 years of experience.
Mr. Thornton joined the Board in July of 2017. Mr. Thornton currently serves as Chief Financial Officer of Technopath Clinical Diagnostics, an Irish company that provides quality control materials and software solutions to clinical laboratories, a position he has held since January 2014. Prior to joining Technopath Clinical Diagnostics, from September 2011 to December 2013 Mr. Thornton was Senior Vice President - Business Integration for Alkermes plc, a global biopharmaceuticals company headquartered in Dublin, Ireland; 17 from July 2007 to September 2011 he was Senior Vice President - Corporate and Business Development for Elan Drug Technologies, an Elan Corporation plc division engaged in developing and manufacturing drug delivery technology based pharmaceutical products; from September 2006 to July 2007 he was President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical company; and from June 2004 to September 2006 he was Chief Financial Officer of Agenus Inc., a NASDAQ-listed biotechnology company. Mr. Thornton worked for the international public accounting firm of KPMG for seven years in Ireland and France and is a fellow of Chartered Accountants Ireland. He brings over 25 years of experience to the Audit, Nominating and Corporate Governance Committees.
Linda S. Palczuk
Ms. Linda S. Palczuk was elected to the board of directors in July of 2018. She serves as the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, a position she has held since February 2018. Prior to joining Verrica Pharmaceuticals, from July 2017 to February 2018, Ms. Palczuk was President and Chief Executive Officer at Osiris Therapeutics, Inc., a regenerative medicines biotechnology company. Prior to her position at Osiris Therapeutics, Ms. Palczuk had an extensive and successful 30-year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior-level commercial and general management roles, including Vice President, Established Brands; Vice President, Global Commercial Excellence; Vice President, Sales & Marketing and Vice President, Sales. Ms. Palczuk received her undergraduate degree in Biology from Franklin and Marshall College and an MBA from the Alfred Lerner College of Business and Economics at the University of Delaware.
Mr. Kotler is an experienced healthcare investor with a strong track record and over 25 years of industry experience. He founded Broadfin Capital, a healthcare focused investment firm based in New York City, in 2005. Mr. Kotler also serves as a director of publicly traded BioDelivery Sciences International, Inc. (Nasdaq: BDSI).
Dr. Eric Ende
Dr. Ende currently serves as President of Ende BioMedical Consulting Group and as a member of Matinas Biopharma’s Board of Directors. Previously he served on the Board of Directors of Genzyme from 2010 until it was acquired by Sanofi-Aventis in 2011 for $20 billion. During his tenure on Genzyme’s Board of Directors, Dr. Ende was a member of the Audit and Risk Management Committees. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 to 2002, Dr. Ende served as the senior biotechnology analyst at Bank of America Securities and, from 1997 to 2000, he served as a biotechnology analyst at Lehman Brothers.